摘要
目的:观察硫酸镁联合硝苯地平对子痫前期患者血清同型半胱氨酸(Hcy)、胎盘生长因子(PLGF)水平及妊娠结局的影响.方法:选取2017年7月-2019年6月就诊于本院的82例子痫前期患者,按随机数字表法将其分为对照组和观察组,各41例.对照组接受硫酸镁治疗,观察组加用硝苯地平治疗.对比两组临床疗效、Hcy与PLGF水平、围生儿不良结局及不良妊娠结局.结果:观察组总有效率为92.68%,高于对照组的75.61%,观察组围生儿不良结局发生率为9.76%,低于对照组的26.83%,差异均有统计学意义(P<0.05).治疗后,两组Hcy水平均低于治疗前,PLGF水平均高于治疗前,但两组比较差异均无统计学意义(P>0.05).两组不良妊娠结局发生情况比较,差异无统计学意义(P>0.05).结论:子痫前期患者接受硫酸镁、硝苯地平联合治疗均有助于调节血清Hcy、PLGF水平,减轻患者症状,改善围生儿不良结局,提升子痫前期治疗效果.
Objective:To observe the effect of Magnesium Sulfate combined with Nifedipine on serum homocysteine(Hcy),placental growth factor(PLGF)levels and pregnancy outcome in patients with preeclampsia.Method:A total of 82 patients with preeclampsia admitted to our hospital from July 2017 to June 2019 were selected,they were divided into the control group and the observation group according to random number table method,41 cases in each group.The control group was treated with Magnesium Sulfate treatment,the observation group was treated with Nifedipine.The clinical efficacy,Hcy and PLGF levels,adverse perinatal infants outcomes and pregnancy outcomes were compared between two groups.Result:The total effective rate of the observation group was 92.68%,higher than 75.61%of the control group,the incidence of adverse outcomes of perinatal infants in the observation group was 9.76%,lower than 26.83%of the control group,with statistically significant differences(P<0.05).After treatment,Hcy level of two groups were lower than those of before treatment,PLGF level were higher than those of before treatment,but the differences between two groups were not statistically significant(P>0.05).There was no significant difference in the adverse pregnancy outcomes between two groups(P>0.05).Conclusion:The combination of Magnesium Sulfate and Nifedipine in preeclampsia patients can help to regulate serum Hcy and PLGF levels,reduce symptoms,improve perinatal adverse outcomes,improve the efficacy of preeclampsia treatment.
作者
舒俊俊
范博群
晏三华
SHU Junjun;FAN Boqun;YAN Sanhua(The Third Affiliated Hospital of Nanchang University(Nanchang First Hospital),Nanchang 330008,China;不详)
出处
《中国医学创新》
CAS
2020年第36期122-125,共4页
Medical Innovation of China
基金
江西省卫生计生委科技计划项目(20177014)
南昌市指导性科技计划项目(洪科发计字[2018]39号)。
